6533b823fe1ef96bd127f498

RESEARCH PRODUCT

Epidemiology of Mantle Cell Lymphoma: A Population-Based Study in France

subject

description

Abstract Abstract 5222 Introduction: Mantle cell lymphoma (MCL) is an aggressive and rare B-cell lymphoma entity representing around 5–8% of non-Hodgkin's lymphomas in adults. To our knowledge no data is available on the epidemiology of MCL in France. We aimed to describe incidence, survival and main clinical characteristics of MCL in a French population. Methods: Patients diagnosed with MCL were identified in three administrative areas covered by an haematological malignancies registry: the Côte d'Or (from 1988 to 2008), the Basse-Normandie (from 1997 to 2006) and the Gironde (from 2002 to 2006). Main clinical features and management characteristics were collected. World age-standardised incidence rates, observed survival and relative survival were estimated for the period 2002–2006. Results: Mantle cell lymphoma was diagnosed in 213 patients over the whole period. Seventy percent of patients were males. Over the period 2002–2006, the age-standardised incidence rate of MCL (per 100,000) was 0.72 in men (n=100) and 0.17 in women (n=35). The median age at diagnosis was 72 years (range: 30–92). Late-stage (III-IV) MCL was diagnosed in 81.5% of patients. MCL international prognostic index (MIPI) was lower or equal to intermediate risk in 36% of patients. The median relative survival time was 41 months (95% confidence interval: 38–62) and was significantly higher in patients with a low or intermediate MIPI (74 months, CI95%: 53–91) than in patients with a high risk (38 months, CI95%: 30–49). Treatment included frontline chemotherapy in 85% patients and 54% patients received rituximab. Ten percent of patients participated in a clinical trial. Conclusion: Epidemiological characteristics of MCL in France were quite similar to epidemiological data reported in other industrialized countries. Incidence rates were characterized by a male-to-female ratio of 4:1. Median overall survival was less than 4 years. Disclosures: No relevant conflicts of interest to declare.